SCYNEXIS Names Sanjay Subramanian Chief Financial Officer

By Public Technologies
  • SCYNEXIS appointed Sanjay S. Subramanian CFO effective September 9, 2026; previously Inozyme Pharma's CFO and head of business development.
  • Subramanian succeeds Ivor Macleod, who retired September 9 and remained through October 9 to support the transition.
  • Todd Minga, a nephrologist with over two decades of kidney-disease research experience, became senior vice president, research and development, effective September 14.
  • Steven K. Burke joined the board effective September 18, serving on the Nominating and Corporate Governance Committee.
  • Burke previously served as Akebia Therapeutics' senior vice president, chief research and development officer and chief medical officer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050820PRIMZONEFULLFEED9870822) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk